Cargando…

Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study

OBJECTIVE: The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy. METHODS: We analyzed the data from the SELECT BC study, a multicenter, ope...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagiwara, Yasuhiro, Shiroiwa, Takeru, Shimozuma, Kojiro, Kawahara, Takuya, Uemura, Yukari, Watanabe, Takanori, Taira, Naruto, Fukuda, Takashi, Ohashi, Yasuo, Mukai, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805818/
https://www.ncbi.nlm.nih.gov/pubmed/29043567
http://dx.doi.org/10.1007/s40273-017-0580-7
_version_ 1783299034980548608
author Hagiwara, Yasuhiro
Shiroiwa, Takeru
Shimozuma, Kojiro
Kawahara, Takuya
Uemura, Yukari
Watanabe, Takanori
Taira, Naruto
Fukuda, Takashi
Ohashi, Yasuo
Mukai, Hirofumi
author_facet Hagiwara, Yasuhiro
Shiroiwa, Takeru
Shimozuma, Kojiro
Kawahara, Takuya
Uemura, Yukari
Watanabe, Takanori
Taira, Naruto
Fukuda, Takashi
Ohashi, Yasuo
Mukai, Hirofumi
author_sort Hagiwara, Yasuhiro
collection PubMed
description OBJECTIVE: The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy. METHODS: We analyzed the data from the SELECT BC study, a multicenter, open-label, randomized, phase III study conducted in Japan, which compared first-line S-1 with taxane therapies. Heath utility and HRQOL were assessed using the EQ-5D-3L and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline and 3, 6, and 12 months after treatment initiation. Health utility was calculated based on societal preferences, and AEs were reported at each cycle of the study treatment. Linear marginal mean models were used to quantify the impact of the last AEs (with 10 or more incidences) observed before HRQOL assessment on health utility and HRQOL. RESULTS: Analysis included 380 patients and 12 (of 15) AEs. Grade 1 nausea and oral mucositis, grade 1 and 2 edema, and grade 2 fatigue, motor and sensory neuropathy, and myalgia were significantly associated with disutility, measured using the EQ-5D-3L. Grade 1 oral mucositis, grade 1 and 2 fatigue, and grade 2 sensory neuropathy were significantly associated with impaired global health status in the EORTC QLQ-C30. AEs associated with decrements in the five functioning scales included fatigue, oral mucositis, nausea, edema, motor and sensory neuropathy, and myalgia. CONCLUSIONS: We reported disutilities caused by AEs in patients with metastatic breast cancer under chemotherapy. These findings can be applied to future model-based cost-effectiveness analyses. TRIAL REGISTRATION NUMBER: C000000416. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40273-017-0580-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5805818
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-58058182018-02-14 Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study Hagiwara, Yasuhiro Shiroiwa, Takeru Shimozuma, Kojiro Kawahara, Takuya Uemura, Yukari Watanabe, Takanori Taira, Naruto Fukuda, Takashi Ohashi, Yasuo Mukai, Hirofumi Pharmacoeconomics Original Research Article OBJECTIVE: The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy. METHODS: We analyzed the data from the SELECT BC study, a multicenter, open-label, randomized, phase III study conducted in Japan, which compared first-line S-1 with taxane therapies. Heath utility and HRQOL were assessed using the EQ-5D-3L and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline and 3, 6, and 12 months after treatment initiation. Health utility was calculated based on societal preferences, and AEs were reported at each cycle of the study treatment. Linear marginal mean models were used to quantify the impact of the last AEs (with 10 or more incidences) observed before HRQOL assessment on health utility and HRQOL. RESULTS: Analysis included 380 patients and 12 (of 15) AEs. Grade 1 nausea and oral mucositis, grade 1 and 2 edema, and grade 2 fatigue, motor and sensory neuropathy, and myalgia were significantly associated with disutility, measured using the EQ-5D-3L. Grade 1 oral mucositis, grade 1 and 2 fatigue, and grade 2 sensory neuropathy were significantly associated with impaired global health status in the EORTC QLQ-C30. AEs associated with decrements in the five functioning scales included fatigue, oral mucositis, nausea, edema, motor and sensory neuropathy, and myalgia. CONCLUSIONS: We reported disutilities caused by AEs in patients with metastatic breast cancer under chemotherapy. These findings can be applied to future model-based cost-effectiveness analyses. TRIAL REGISTRATION NUMBER: C000000416. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40273-017-0580-7) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-10-17 2018 /pmc/articles/PMC5805818/ /pubmed/29043567 http://dx.doi.org/10.1007/s40273-017-0580-7 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Hagiwara, Yasuhiro
Shiroiwa, Takeru
Shimozuma, Kojiro
Kawahara, Takuya
Uemura, Yukari
Watanabe, Takanori
Taira, Naruto
Fukuda, Takashi
Ohashi, Yasuo
Mukai, Hirofumi
Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
title Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
title_full Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
title_fullStr Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
title_full_unstemmed Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
title_short Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
title_sort impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the select bc study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805818/
https://www.ncbi.nlm.nih.gov/pubmed/29043567
http://dx.doi.org/10.1007/s40273-017-0580-7
work_keys_str_mv AT hagiwarayasuhiro impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy
AT shiroiwatakeru impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy
AT shimozumakojiro impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy
AT kawaharatakuya impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy
AT uemurayukari impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy
AT watanabetakanori impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy
AT tairanaruto impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy
AT fukudatakashi impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy
AT ohashiyasuo impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy
AT mukaihirofumi impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy